An abstract presented at CHEST 2021 showed that women who entered pregnancy with sleep-disordered breathing were associated with higher levels of insulin resistance and potential risk of gestational diabetes.
Incidence and severity of sleep-disordered breathing (SDB) early in pregnancy may increase risk of insulin resistance, according to abstract findings presented at the CHEST 2021 Annual Meeting.
Typically thought to occur late in pregnancy, the relationship between SDB and abnormal glucose metabolism has been indicated to increase potential risk of gestational diabetes. However, researchers note that it remains unclear whether this relationship starts in early pregnancy or develops following exposure to SDB in pregnancy.
“This is significant because relationships between early pregnancy SDB and insulin resistance are largely unstudied,” the study authors said.
Seeking to assess the association between SDB and its severity with glucose metabolism in early pregnancy, they examined women with singleton pregnancies who had risk factors for obstructive sleep apnea (OSA), a form of SDB that has been linked with high blood pressure, cardiovascular disease, and Alzheimer disease.
Including pregnant women with OSA risk factors, such as body mass index (BMI) greater than or equal to 27 kg/m2 and habitual snoring, participants underwent in-home level III sleep apnea testing (HSAT) and homeostatic model assessment (HOMA) based on fasting glucose and C-peptide levels in early pregnancy (N = 192).
Use of chronic steroid therapy, history of pregestational diabetes, and use of continuous positive airway pressure were noted as exclusion criteria for the study.
“We derived measures of SDB (respiratory-event index [REI] and oxygen saturation index [ODI]) and glucose metabolism parameters (insulin resistance [HOMA-IR] and ꞵ-cell function [HOMA-%B]),” they added. “HSAT and HOMA were performed at a median gestational age (interquartile range) of 11 (3) and 15 (4) weeks, respectively.”
Of the study cohort, 61 participants (32%) were diagnosed with OSA, as measured by REI values greater than or equal to 5 events per hour. After adjusting for gestational age at testing, maternal age, BMI, ethnicity, and race, findings showed that women diagnosed with OSA had higher levels of insulin resistance than those not diagnosed.
In performing linear regression analysis and analysis of variance to examine the association between measures of SDB and glucose metabolism parameters, REI, as a continuous value, was significantly associated with HOMA-IR (B = 0.18; P = .041).
Conversely, OSA diagnosis (REI ≥ 5 events/hour) was not associated with HOMA-IR after adjusting for BMI (P > .05), with ODI significantly associated with HOMA-IR prior to adjusting for covariates (B = 0.22; P = .002), but not after adjustment (P = .24). No significant associations were observed between REI or ODI and HOMA-%B (P > .34).
“Our data suggest that women with SDB may enter pregnancy at a higher risk for gestational diabetes, instead of developing that risk over the course of pregnancy,” concluded the researchers. “This could imply SDB screening and treatment should occur earlier in pregnancy.”
They added that further investigation is warranted to investigate if treatment for SDB in early pregnancy could improve glucose metabolism.
Reference
Bai A, Sanapo L, Bublitz M, et al. Association between sleep disordered breathing and glucose metabolism in early pregnancy. CHEST. Published online October 1, 2021. doi:10.1016/j.chest.2021.07.2089
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More